Guerbet LLC USA, the U.S. affiliate of the global specialist in contrast media products and solutions for diagnostic and interventional imaging, is pleased to support the sixth annual Melanoma Research Foundation Gala in Philadelphia, PA.
PRINCETON, N.J., June 3, 2019 -- Guerbet LLC USA, the U.S. affiliate of the global specialist in contrast media products and solutions for diagnostic and interventional imaging, is pleased to support the sixth annual Melanoma Research Foundation Gala in Philadelphia, PA.
David Eschelman, MD and his team from Thomas Jefferson University Hospital will be honored with the Melanoma Research Foundation’s (MRF) CURE OM Vision of Hope Award at this year’s gala on Thursday, June 6th at Water Works, 640 Waterworks Drive in Philadelphia.
"Guerbet is proud to support the Melanoma Research Foundation’s critical mission to raise funds in support of melanoma research, education and advocacy,” said Massimo Carrara, Guerbet Vice President for North America. "As a global leader in medical imaging, we are excited to partner with Thomas Jefferson University Hospital and David Eschelman, a long-time advocate for uveal melanoma patients and research, to support the Melanoma Research Foundation (MRF) to fund research that brings us closer to a cure."
The contribution emphasizes Guerbet’s commitment to advancing research that supports the highest quality of care to patients in diagnostic and interventional imaging. Guerbet has previously provided medical education grants to Jefferson for CURE OM, a patient-centered educational program on Uveal Melanoma.
The Melanoma Research Foundation’s Philadelphia Gala is a signature food and cocktail tasting
event in Philadelphia. Funds raised at the Philadelphia Gala help support the Foundation’s mission to fund medical research for finding effective treatments and eventually a cure for melanoma.
ABOUT GUERBET
Guerbet is a pioneer in the contrast-agent field, with more than 90 years’ experience, and is a leader in medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices, and services for diagnostic and interventional imaging to improve the diagnosis and treatment of patients. With 8% of revenue dedicated to R&D and more than 200 employees distributed across its four centres in France, Israel, and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €790 million in revenue in 2018. For more information about Guerbet, please visit www.guerbet.com
MEDIA RELATIONS
Guerbet US
Audrey Wallendal
US (609) 683-0700
awallendal@taftcommunications.com
